Diabetes mellitus has become a widespread chronic non-communicable disease worldwide, while China has the highest number of patients worldwide, with a prevalence as high as 12.8%, which is much higher than the world average of 8.8%. However, the awareness rate, treatment rate and control rate of blood glucose for diabetes mellitus in China are low, and the management situation is very severe.
Kaiyu (Vildagliptin Tablets) of Tide Pharmaceutical, a DPP-4 inhibitor, is one of the first-line hypoglycemic drugs for the treatment of diabetes mellitus. Early combination with metformin can more effectively control blood glucose and delay the process of diabetes, with good tolerance and safety.
This product is indicated to treat type 2 diabetes mellitus.
- This product can be used as monotherapy when blood glucose cannot be effectively controlled by diet and exercise;
- This product may be combined with metformin when metformin as monotherapy still cannot effectively control blood glucose at its maximum tolerated dose;
- This product may be combined with insulin when insulin cannot effectively control blood glucose at the stable dose;
-This product may be combined with sulphonylureas when sulphonylureas cannot effectively control blood glucose at the stable dose.
This product is white to yellowish tablet.
【Dosage and Administration】
When vildagliptin is used as monotherapy or is combined with metformin or combined with insulin (with or without metformin), the recommended daily dose of vildagliptin is 100 mg, bid, with 50 mg in the morning and 50 mg in the evening.
When vildagliptin is combined with sulphonylureas, the recommended daily dose of vildagliptin is 50 mg, qd, and it is recommended to administer in the morning. Lower dose of sulfonylureas may also be considered to reduce the risk of hypoglycemia.
A dose of more than 100mg is not recommended.
This product can be taken with or without food (please refer to 【Pharmacokinetics】).
Kaiyu (Vildagliptin Tablets)